the Study will be conducted according to international standards, the effectiveness of the drug combination will be determined compared to combination of placebo and ramdevpir in patients with severe pneumonia caused by a novel coronavirus.

the Study, named REMDACTA, has an international status: it involved medical research centers in the U.S., Brazil and Russia. In our country it involves six leading clinics in Moscow and Saint-Petersburg City clinical hospital No. 15 named after O. M. Filatov”(Moscow), Military medical Academy named after S. M. Kirov (Saint Petersburg), Infectious clinical hospital N1(Moscow), “Medsi” (Moscow), Pokrovskaya City hospital (St.-Petersburg), City clinical hospital N52 (Moscow). It is planned that, in General, the study will involve 450 patients, 160 of them in our country.

Tocilizumab – drug based on human monoclonal antibodies, which is used to treat rheumatoid arthritis and some other severe inflammations. It is not yet registered in any country of the world for the indication of treatment of patients with COVID-19, but exceptionally allowed in many countries for use in patients COVID-19 during a pandemic to prevent the cytokine storm. Russia also has experience of its use: the drug is included into the Provisional guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)” the Ministry of health of the Russian Federation (the seventh, the updated version from 03.06.2020).